Nkgen Biotech, INC 8-K filings

NKGen Biotech received notice from Nasdaq withdrawing a deficiency letter related to minimum market value, but the company's delisting appeal remains pending with a hearing scheduled for October 31, 2024.

NKGen Biotech issued approximately 492,800 shares of common stock to a convertible note holder, triggering a reset of conversion and exercise prices for outstanding notes and warrants.

NKGen Biotech has appointed Michael Klowden and Kathleen Scott as new directors, filling vacancies created by recent resignations, and assigned them to key committee roles.

NKGen Biotech reports the resignation of three directors, effective September 29, 2024, reducing the board size to two members.

NKGen Biotech received a notice from Nasdaq regarding its non-compliance with the minimum bid price requirement, placing its listing status at risk.

NKGen Biotech issued approximately 162,000 shares of common stock to convertible note holders, leading to a reset of conversion and warrant exercise prices.

NKGen Biotech is appealing Nasdaq's decision to delist its common stock from the Global Market due to non-compliance with market value requirements and intends to transfer to the Nasdaq Capital Market.

NKGen Biotech has received a delisting notice from Nasdaq after failing to meet market value and filing requirements, and is planning to appeal the decision.

NKGen Biotech has amended its forward purchase agreement with Meteora Capital Partners, increasing the prepayment shortfall by $250,000 and issuing an additional 250,000 shares.

NKGen Biotech highlighted its SNK cell therapy platform and clinical trial results for neurodegenerative diseases and cancer at the H.C. Wainwright 26th Annual Global Investment Conference.

NKGen Biotech held its annual meeting on August 28, 2024, where stockholders elected a Class I director and approved a proposal for potential share issuance.

NKGen Biotech has received a notification from Nasdaq for failing to file its quarterly report on time, primarily due to a change in accounting firms.

NKGen Biotech's Chief Operating Officer, Pierre Gagnon, has resigned, effective immediately, but will remain in an advisory role until November 30, 2024.

NKGen Biotech has entered into a securities purchase agreement, issuing a promissory note and warrants to CFIC-2015 NV Family Investments, LLC, for a total of $2.75 million.

NKGen Biotech has amended its forward purchase agreement, increasing the prepayment shortfall by $211,802.20 and allowing for the potential issuance of 248,360 additional shares.

NKGen Biotech has amended its forward purchase agreement with Polar Multi-Strategy Master Fund, extending the valuation date and modifying key terms.

NKGen Biotech has replaced Ernst & Young with WithumSmith+Brown as its independent registered public accounting firm, effective for the fiscal year ending December 31, 2024.

NKGen Biotech has amended its forward purchase agreement, increasing the prepayment shortfall by $200,000 and issuing an additional 200,000 shares of common stock.

NKGen Biotech has appointed Dr. Marco Gottardis to its Board of Directors and key committees, effective July 11, 2024, filling a vacancy created by a previous resignation.

NKGen Biotech has issued a second tranche of a common stock purchase warrant and promissory note to AJB Capital Investments, as part of a previously disclosed securities purchase agreement.

NKGen Biotech and Generating Alpha Ltd. amended their securities purchase agreement to include a beneficial ownership limitation.

NKGen Biotech has entered into multiple securities purchase agreements, issuing promissory notes and warrants to raise capital.

NKGen Biotech has amended its warrant and debt agreements, delaying conversion rights and resetting exercise prices, while also securing forbearance on debt repayment triggers.

NKGen Biotech has amended its forward purchase agreement to establish a floor on the reset price of shares, providing a minimum price of $1.2743.

NKGen Biotech has secured a $5 million second lien convertible loan to support its clinical programs in neurodegenerative diseases and oncology.

NKGen Biotech has entered into agreements to issue promissory notes and warrants, raising a total of $550,000 in funding.

NKGen Biotech has entered into agreements to issue promissory notes and warrants totaling $660,000 to FirstFire Global Opportunities Fund and Meteora, providing the company with additional capital.

NKGen Biotech's board of directors has appointed Dr. Paul Y. Song as the new chairperson, following Sangwoo Park's decision to step down from the role while remaining a director.

NKGen Biotech received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, but has until September 9, 2024, to regain compliance.

NKGen Biotech has amended its forward purchase agreement, increasing the prepayment shortfall by $200,000 and the share consideration by 200,000 shares.